SUPN vs LNTH
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SUPN · Supernus Pharmaceuticals$28.61 ▲ 0.92%
LNTH · Lantheus$102.10 ▲ 0.00%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SUPN -36.6%
- LNTH +80.7%
Head to head
| Metric | SUPN | LNTH |
|---|---|---|
| Price | $28.61 | $102.10 |
| Change today | ▲ 0.92% | ▲ 0.00% |
| Market cap | $5.94B | $6.68B |
| Return, 3 months | -36.6% | +1.3% |
| Return, year to date | -42.4% | +53.4% |
| Return, 1 year | -36.9% | +82.9% |
| P/E (TTM) | – | 25.4 |
| P/B | 5.6 | 4.9 |
| P/E percentile vs own 5y | 20th | 68th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +18.0% | +1.5% |
| Net profit growth (YoY) | +146.4% | -19.4% |
| Gross margin | 87.6% | 61.3% |
| Operating margin | 3.2% | 18.6% |
| Net margin | -5.1% | 17.3% |
| Return on equity | -4.2% | 21.8% |
| Analyst target vs. price | +83.9% | +5.0% |
| Analyst buy share | 83% | 0% |
| RSI (14) | 36 | 69 |
| 30-day volatility | 127.6% | 4.1% |
| Max drawdown, 1 year | -53.6% | -12.2% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LNTH is the largest of the group by market value.
- LNTH has returned the most over the past year.
- SUPN is growing revenue fastest.
- LNTH keeps the most profit per dollar of sales.
- LNTH has been the calmest stock over the last 30 days.